Search

Displaying results 5011 - 5020 of 7018 in total
  1. Drug

    Imexon

    go.drugbank.com/drugs/DB05003
    Investigational

    Imexon is a thiol-binding small molecule which induces mitochondrial oxidation, a loss of membrane potential and cytochrome C, leading to apoptosis. … It belongs to the family of drugs called cyanoaziridine derivatives. Also called Amplimexon. Imexon is a cyanoaziridine derivative.

  2. Drug

    SGS518

    go.drugbank.com/drugs/DB05042
    Experimental

    SGS518, a novel antagonist for the 5HT6 subtype of the serotonin receptor, is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).

  3. Drug

    (R)-acetoin

    go.drugbank.com/drugs/DB04364
    Experimental

    A product of fermentation. It is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.

  4. Drug

    (S)-acetoin

    go.drugbank.com/drugs/DB02788
    Experimental

    A product of fermentation. It is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.

  5. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and atherosclerosis.

  6. Drug

    Thymectacin

    go.drugbank.com/drugs/DB05116
    Investigational

    Thymectacin was as efficacious as irinotecan, a drug recently approved for the treatment of 5-fluorouracil-resistant colon cancer. … Thymectacin, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine, is a novel small molecule anticancer agent.

  7. Drug

    CMC 001

    go.drugbank.com/drugs/DB05353
    Investigational

    CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.

  8. Drug

    ATHX-105

    go.drugbank.com/drugs/DB06008
    Investigational

    ATHX-105 is an investigational selective 5HT2c receptor agonist developed by Athersys Inc. for the treatment of Obesity.

  9. Drug

    KB-141

    go.drugbank.com/drugs/DB03176
    Experimental

    An anticholesteremic agent.

  10. Drug

    UC-781

    go.drugbank.com/drugs/DB05871
    Investigational

    UC-781 is a thiocarboxanilide non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a topical microbicide targeted against the AIDS virus.